Sort   by:  
 Page size 
ProteomicsEvaluation of phospho-tyrosine antibodies for label-free phosphoproteomics
In the past decade multiple tyrosine kinase inhibitors (TKIs) have been implemented in standard treatment regimens for patients with cancer. Unfortunately the majority of patients develops resistance to these drugs. Reliable tools for analysis of pharmacodynamic effects and drug resistance mechanism...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2016-10-21 | MSV000080270 | MassIVE
ProteomicsPredictive data-driven modeling of C-terminal tyrosine function in the EGFR signaling network
The Epidermal Growth Factor Receptor (EGFR) has been studied extensively due to its critical role in cellular signaling and association with disease. Previous models have elucidated interactions between EGFR and downstream adaptor proteins, or showed phenotypes affected by EGFR. However, the link be...
ORGANISM(S): Mus musculus (Mouse) 
2023-05-09 | PXD032403 | Pride
Egfr phosphoproteomics phosphorylation signaling tyrosine 
ProteomicsA quantitative phosphoproteomic analysis to study the dynamics of tyrosine phosphorylation in EGFR signaling abrogated by TKIs
Lung cancer is the leading cause of cancer death. Mutations in the kinase domain of EGFR, a predominant driver oncogene, such as L858R missense mutation and a series of deletions spanning the conserved sequence 747LREA750, are associated with sensitivity to tyrosine kinase inhibitors (TKIs). However...
ORGANISM(S): Homo sapiens (Human) 
2017-03-29 | PXD004373 | Pride
Nsclc Phosphoproteomics Tki Egfr Adenocarcinoma 
ProteomicsDIA-MS Detect the Targeted EGFR Dephosphorylation by Phosphorylation Targeting Chimera (PhosTAC)
Epidermal growth factor receptor (EGFR) is an important receptor tyrosine kinase protein. Activated EGFR promotes downstream signal transductions through phosphorylation, and its phosphorylation has been implicated in pathologies including many types of cancers. Previously, our lab has developed the...
ORGANISM(S): Homo sapiens (Human) 
2024-04-02 | PXD038022 | Pride
Phosphoproteomics Dia-ms Phostac Egfr Kinase 
ProteomicsParallel phosphoproteomics and metabolomics map the global metabolic tyrosine phosphoproteome
Tyrosine phosphorylation of metabolic enzymes is an evolutionarily conserved post-translational modification that facilitates rapid and reversible modulation of enzyme activity, localization or function. Despite the high abundance of tyrosine phosphorylation events detected on metabolic enzymes in h...
ORGANISM(S): Homo sapiens (Human) 
2025-05-06 | PXD052217 | Pride
Metabolomics Egf signaling Phosphoprotoemics Tyrosine phosphorylation 
ProteomicsSILAC-based quantitative tyrosine phosphoproteomic profiling identifies alternative therapeutic targets to erlotinib in head and neck squamous cell carcinoma
Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase is overexpressed in 90% of Head and neck squamous cell carcinoma (HNSCC) patients. Clinical trials with EGFR-targeted tyrosine kinase inhibitors such as erlotinib have shown a modest activity in HNSCC alternate mechanisms of resist...
ORGANISM(S): Homo sapiens (Human) 
2022-10-13 | PXD007769 | Pride
Head and neck cancer Mass spectrometry Signaling pathways Quantitative proteomics Egfr-tyrosine kinase inhibitor resistance 
OtherIdentifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Data from ProteomeXchange, PXD ID: PXD001101. Experiment: pST_SILAC_R1a, file: H3255_pST_SILAC_R1_F4_a.mzml. Published as part of Proteomics. 2015 Jan;15(2-3):340-55 . From the Abstract: {{i}} . We sought to identify the immediate direct and indirect phosphorylation targets of mutant EGFRs in lung ...
ORGANISM(S): Homo_sapiens_viruses, Human 
GPM32320007613 | GPMDB
Resource Reanalysis 
ProteomicsIntegrated proteomics-based physical and functional mapping of AXL kinase signaling pathways and inhibitors define its role in cell migration: Phosphoproteomics
To better understand the signaling complexity of AXL, a member of the TAM family of receptor tyrosine kinases, we created a physical and functional map of AXL signaling interactions, phosphorylation events, and target-engagement of three AXL tyrosine kinase inhibitors (TKI). We assessed AXL protein-...
ORGANISM(S): Homo sapiens (Human) 
2022-10-14 | PXD023923 | Pride
Phosphoproteomics Lung cancer Targeted therapy Axl tyrosine kinase 
ProteomicsIdentifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics
Mutations in the epidermal growth factor receptor (EGFR) kinase domain occur in 10-30% of lung adenocarcinoma. Leucine to arginine substitution at amino acid position 858 (L858R) accounts for around 50% of EGFR-tyrosine kinase inhibitor (TKI) sensitizing mutations. A second site mutation in the gate...
ORGANISM(S): Homo sapiens (Human) 
2015-01-30 | PXD001101 | Pride
Nsclc Phosphoproteomics Tki Egfr Adenocarcinoma 
ProteomicsMig6 mediates adaptive and acquired resistance to ALK and ROS1 fusion kinase inhibition through feedback activation of EGFR: Cuto28
ALK and ROS1 fusions defines subsets of lung adenocarcinoma. Although ALK/ROS1 inhibitors improved therapeutic outcome of patients harboring those oncogenic fusions, complete responses were rare, and resistance eventually develops from the residual tumor. To under the mechanisms contributing to resi...
ORGANISM(S): Homo sapiens (Human) 
2023-09-12 | PXD036771 | Pride
Lung cancer Kinase inhibitor Anaplastic lymphoma kinase Drug resistance 
Sort   by:  
 Page size